Similar articles

• Risk of AIDS and death at given HIV-RNA and CD4 cell count, in relation to specific antiretroviral drugs in the regimen.

  Olsen CH, Gatell J, Ledergerber B, Katlama C, Friis-Møller N, Weber J, Horban A, Staszewski S, Lundgren JD, Phillips AN; EuroSIDA Study Group. Olsen CH, et al. AIDS. 2005 Feb 18;19(3):319-30. AIDS. 2005. PMID: 15718843
• Anti-HIV-1 intermittent drug intensification in HIV-1-infected patients naive for antiretrovirals.

  Rusconi S, Argenteri B, Galli M, d'Arminio-Monforte A, Moroni M. Rusconi S, et al. Antivir Ther. 1999;4(3):183-4. Antivir Ther. 1999. PMID: 12731759 Clinical Trial. No abstract available.
• Questions about HIV causing AIDS? Viral load and T-cell (CD4) counts: why they really matter.

  [No authors listed] [No authors listed] AIDS Treat News. 2001 May 11;(364):7-8. AIDS Treat News. 2001. PMID: 11569964 No abstract available.
• Immune reconstitution inflammatory syndrome.

  Surjushe AU, Jindal SR, Kamath RR, Saple DG. Surjushe AU, et al. Indian J Dermatol Venereol Leprol. 2006 Nov-Dec;72(6):410-4. doi: 10.4103/0378-6323.29335. Indian J Dermatol Venereol Leprol. 2006. PMID: 17179614 Review. No abstract available.
• Longitudinal models for AIDS marker data.

  Boscardin WJ, Taylor JM, Law N. Boscardin WJ, et al. Stat Methods Med Res. 1998 Mar;7(1):13-27. doi: 10.1177/096228029800700103. Stat Methods Med Res. 1998. PMID: 9533259 Review.